Five Prime’s Phase 1 Trial Begins FPA150 Dosing Among Solid Tumor Patients

Five Prime’s Phase 1 Trial Begins FPA150 Dosing Among Solid Tumor Patients
The Phase 1a/1b trial evaluating Five Prime Therapeutics‘ checkpoint inhibitor FPA150 in patients with advanced solid cancers has begun dosing patients ahead of schedule, the company announced. FPA150 is an antibody that targets the B7-H4 protein in malignant cells. This protein is found in numerous solid tumors and belongs to the family of checkpoint molecules, such as PD-L1,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *